Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,545 signal articles · 139 in last 24h · 154,889 total before filter · latest 1h ago
139last 24h
836last 7d
144● bullish (7d)
87● bearish (7d)
214publishers
AllMacro183Earnings103M&A124Regulatory18Product21Analyst19
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearishshow all (incl. clickbait)
Wells Fargo resets its inflation target for 2026 and 2027
TheStreet38d agoneutral
Wells Fargo resets its inflation target for 2026 and 2027

Wall Street has spent this year waiting for prices to calm down. The thinking was simple. The war with Iran pushed oil up in February; the shock would wear off, and the Fed would go back to cutting rates. One of the banks that sold that idea has changed its mind. Wells Fargo is not a gloomy voice ...

Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum
Insider Monkey38d agobullish
Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

RBC's Lori Calvasina Sees S&P 500 Upside Despite Fed Risk
Bloomberg39d agoneutralVIDEO
RBC's Lori Calvasina Sees S&P 500 Upside Despite Fed Risk

Wall Street traders sent stocks and bonds wavering in the Monday session as fresh Middle East violence stoked concerns about an escalation of the war that has jolted global markets. Following the S&P 500's longest weekly advance since May, the gauge fluctuated. Chipmakers rallied as Anthropic PBC's revenue surge bolstered bets on the artificial-intelligence trade. Brent crude rose to around $89, leaving traders wary about inflationary pressures that could make the Federal Reserve raise rates. Treasury 30-year yields hit the highest since 2007. Lori Calvasina, Head of US Equity Strategy at RBC Capital Markets, explains why Fed policy uncertainty, potential rate hikes and valuation concerns may not be enough to derail the equity rally. She speaks to hosts Tom Keene and Paul Sweeney on Surveillance Radio.

ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?
StockStory39d agoneutral
ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?

ICU Medical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 9.3%. The stock now trades at $182.79, marking a 23.3% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

World shares are mixed and oil prices slip after worries over stagflation pull US stocks lower
Associated Press39d agoneutral
World shares are mixed and oil prices slip after worries over stagflation pull US stocks lower

Such data could help the Federal Reserve keep interest rates low, which is positive for investors. The Fed has no good tool to fix both a stagnating economy and high inflation at the same time, which is why what’s called “stagflation” is seen as a worst-case scenario. Wall Street and economists will get more details about the Federal Reserve’s interest rate policy when the central bank releases minutes from the July meeting on Wednesday.

Earnings Are Crushing It. Stocks are Riding High. Why Isn’t Wall Street Moving on S&P 500 Price Targets?
Barrons.com39d agoneutral
Earnings Are Crushing It. Stocks are Riding High. Why Isn’t Wall Street Moving on S&P 500 Price Targets?

Wall Street is heading into the final stretch of the second-quarter earnings season riding the strongest pace of profit growth in five years—alongside fading bets on a Federal Reserve interest-rate hike, which should support stock performance deep into the autumn. The market’s most-watched analysts, however, are still forecasting end-of-year price targets for the that suggest meager gains over the coming months—even as they predict impressive profit growth over the coming quarters, without fretting too much about the amount investors will pay for it. Gains in the high 20% range are also forecast for both the third and fourth quarters, which would bring full-year growth to around 33.3%, or $360 a share in S&P 500 terms.